We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Crimson Tide Plc | LSE:TIDE | London | Ordinary Share | GB00BRJRV969 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 160.00 | 155.00 | 165.00 | 160.00 | 160.00 | 160.00 | 0.00 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Cmp Processing,data Prep Svc | 5.35M | -1.24M | -0.1891 | -8.46 | 10.52M |
TIDMTIDE
Crimson Tide PLC
05 July 2018
Crimson Tide plc ("Crimson Tide" or the "Company")
Continued investment in mpro5 for healthcare sees GCloud accreditation contract awards.
Crimson Tide is pleased to announce it has continued to add subscribers in the healthcare sector from its investments in R&D and marketing. Critical to our growth in the UK healthcare sector and specifically the public bodies responsible for delivery, it is also with great pleasure that the Company announces that mpro5 has been accepted to GCloud 10, the government marketplace for applications.
A global healthcare organisation has completed a second successful pilot of mpro5 for the identification and reporting of falsified and fraudulent medication. These pilots have been carried out in emerging nations where the effectiveness of contraceptives and anti-malarial medicines are critical to the economic and social development of the country as a whole. mpro5 has positively detected multiple instances of falsified medicine in the pilot areas. The Company is hopeful that further collaboration could lead to full rollouts in the pilot countries and other uses of mpro5 are under discussion.
Crimson Tide is in the process of adding a new biometric time and attendance module to mpro5 for a NHS trust in the North West of England, leveraging scanning capabilities to guarantee correct identification of individuals arriving on site.
The Company has also won a contract to aid AVM Services, which operates within Cambridge University Hospitals NHS Foundation Trust, with decontamination activities which are conducted in accordance with standardised UK regulatory procedures. mpro5 allows the scheduling of regular tasks in respect of porous loads and instruments including sterilizers, disinfectors and endoscopes. The commissioning of decontamination equipment is achieved through an mpro5 workflow that automatically awards the relevant compliance or commissioning document based on a complex scoring method.
A variety of our existing facilities management clients have continued the rollout of 49 point NHS cleaning compliance checks adding an increasing number of healthcare facilities to the locations where mpro5 is in daily use.
Crimson Tide's Executive Chairman, Barrie Whipp commented. "It is pleasing to hear of the NHS commitment to mobile applications for patients. mpro5 is a tactical solution to healthcare scenarios for not only patients, but clinicians and organisations that participate in the healthcare supply chain. We are now GCloud approved allowing us to push on with our investments and bring real change to processes in the state and private sector, locally and internationally"
-- ends --
For further information:
Crimson Tide plc Barrie Whipp / Luke Jeffrey / Steve Goodwin 01892 542 444
Arden Partners plc (Nomad/Broker) Steve Douglas / Dan Gee-Summons 020 7614 5900
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NRAEAXXSEDKPEEF
(END) Dow Jones Newswires
July 05, 2018 03:38 ET (07:38 GMT)
1 Year Crimson Tide Chart |
1 Month Crimson Tide Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions